Real‐life targeted next‐generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network

Summary As the impact of targeted next‐generation sequencing (TNGS) on daily diagnosis has not been evaluated, we performed TNGS (46 genes) on lymphomas of unclear subtype following expert haematopathological review. The potential impact on patient care and modifications of final diagnosis were divi...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2021-06, Vol.193 (6), p.1110-1122
Main Authors: Bommier, Côme, Mauduit, Claire, Fontaine, Juliette, Bourbon, Estelle, Sujobert, Pierre, Huet, Sarah, Baseggio, Lucile, Hayette, Sandrine, Laurent, Camille, Bachy, Emmanuel, Ghesquières, Hervé, Thieblemont, Catherine, Salles, Gilles, Traverse‐Glehen, Alexandra
Format: Article
Language:English
Subjects:
Biopsy
Central nervous system
Diagnosis
DNA sequencing
Hematology
Lymphoma
molecular biology
next‐generation sequencing
pathology
Patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary As the impact of targeted next‐generation sequencing (TNGS) on daily diagnosis has not been evaluated, we performed TNGS (46 genes) on lymphomas of unclear subtype following expert haematopathological review. The potential impact on patient care and modifications of final diagnosis were divided into major and minor changes according to the European Society of Medical Oncology (ESMO) guidelines. Among 229 patients [19 primary central nervous system lymphomas (PCNSL), 48 large B‐cell lymphomas (LBCLs), 89 small BCLs (SBCLs), seven Hodgkin lymphomas (HL), 66 T‐cell lymphomas], the overall concordance rate of histological and TNGS diagnosis was 89·5%. TNGS confirmed the histological diagnosis in 144 cases (62·9%), changed the diagnosis in 24 cases (10·5%) and did not help to clarify diagnosis in 61 cases (26·7%). Modifications to the final diagnosis had a clinical impact on patient care in 8·3% of cases. Diagnostic modifications occurred in all types of lymphoma except in PCNSL and HL; the modification rate was 14·6% in SBCL and 12·5% in LBCL. While comparing informative and uninformative cases, no differences were found in terms of DNA amplification, quality or depth of sequencing and biopsy type. The present study highlights that TNGS may directly contribute to a more accurate diagnosis in difficult‐to‐diagnose lymphomas, thus improving the clinical management in routine practice.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17395